<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Acyclovir - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Acyclovir</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../../index.html">Home</a>
        <a class="btn small" href="../../index.html#/sickbay-meds">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Antibiotics / Antivirals</div>
      <h1>Acyclovir</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Acyclovir 500mg Injection (50mg/mL)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <p><strong>Note:</strong> Stocked formulation is IV injection. Oral acyclovir may be available ashore. Dosing below reflects IV use for severe infections requiring parenteral therapy.</p>
        <ul>
          <li><strong>Herpes simplex encephalitis (severe; emergency)</strong>
            <ul>
              <li>10 mg/kg IV every 8 hours for 14–21 days</li>
              <li>Infuse over at least 1 hour</li>
              <li>Requires evacuation and hospital-level care; initiate only with medical direction in true emergency</li>
            </ul>
          </li>
          <li><strong>Severe mucocutaneous HSV infection (immunocompromised host)</strong>
            <ul>
              <li>5 mg/kg IV every 8 hours for 7–14 days (or until clinical resolution)</li>
              <li>Infuse over at least 1 hour</li>
            </ul>
          </li>
          <li><strong>Varicella-zoster virus (VZV) – severe or disseminated (immunocompromised)</strong>
            <ul>
              <li>10 mg/kg IV every 8 hours for 7–10 days</li>
              <li>Infuse over at least 1 hour</li>
            </ul>
          </li>
          <li><strong>Renal dosing adjustments required</strong>
            <ul>
              <li>Dose adjustment necessary in renal impairment; follow product monograph/medical direction</li>
              <li>Ensure adequate hydration to minimize nephrotoxicity</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Severe herpes simplex virus (HSV) infections (encephalitis, disseminated disease, severe mucocutaneous infection in immunocompromised)</li>
          <li>Varicella-zoster virus (VZV) infections in immunocompromised patients or severe/complicated cases</li>
          <li>Onboard IV acyclovir is primarily for emergency initiation with evacuation planned; most HSV/VZV cases can be managed with oral antivirals (if available) or supportive care</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to acyclovir or valacyclovir</li>
          <li>Renal impairment: nephrotoxicity risk; dose adjustment required; ensure adequate hydration</li>
          <li>Dehydration increases nephrotoxicity risk significantly</li>
          <li>Neurologic toxicity possible (tremor, confusion, hallucinations, seizures) especially with high doses or renal impairment</li>
          <li>Phlebitis/inflammation at infusion site: ensure proper dilution and infusion rate</li>
          <li>Pregnancy: category B; use when benefit outweighs risk</li>
          <li>IV administration requires appropriate training and monitoring</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Nephrotoxicity (crystalluria, acute kidney injury) – especially with rapid infusion or dehydration</li>
          <li>Phlebitis, inflammation at IV site</li>
          <li>Neurologic effects: headache, dizziness, confusion, hallucinations, seizures (higher risk in renal impairment)</li>
          <li>Nausea, vomiting, diarrhea</li>
          <li>Transient elevation in liver enzymes</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li><strong>Reconstitution:</strong> Reconstitute 500 mg vial with 10 mL Sterile Water for Injection to yield 50 mg/mL</li>
          <li><strong>Dilution:</strong> Further dilute in compatible IV solution (e.g., Normal Saline or D5W) to concentration ≤7 mg/mL (typically 100 mL to 250 mL depending on dose)</li>
          <li><strong>Infusion rate:</strong> Administer over at least 1 hour (do NOT give as bolus or rapid infusion—nephrotoxicity risk)</li>
          <li><strong>Hydration:</strong> Ensure adequate hydration before and during therapy to reduce crystalluria risk</li>
          <li>Use within appropriate timeframe after reconstitution/dilution (check product monograph for stability)</li>
          <li>Monitor IV site for phlebitis; rotate sites as needed</li>
          <li><strong>Do NOT administer IM or subcutaneously</strong></li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Renal function (creatinine, urine output) before and during therapy—critical in IV use</li>
          <li>Hydration status and fluid balance</li>
          <li>Neurologic status (mental status changes, seizures—especially if renal impairment)</li>
          <li>IV site for phlebitis/extravasation</li>
          <li>Clinical response to therapy (viral symptoms, fever)</li>
          <li>Electrolytes if prolonged use or renal concerns</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>IV acyclovir is a high-acuity medication requiring intensive monitoring—use only in true emergencies with medical direction and evacuation planning</li>
          <li>For most HSV/VZV infections onboard: consider oral acyclovir (if available locally) or supportive care; reserve IV for life-threatening/severe disease</li>
          <li>Limited lab capability: if renal function monitoring not available, use with extreme caution and prioritize evacuation</li>
          <li>Hydration paramount: ensure IV fluids concurrently to reduce nephrotoxicity risk</li>
          <li>Training requirement: ensure qualified personnel for IV administration and monitoring</li>
          <li>Communicate clearly with receiving facility: medication given, dose, time, and clinical indication</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (acyclovir injection): <a href="https://pdf.hres.ca/dpd_pm/00068225.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00068225.PDF</a></li>
          <li>BC Centre for Disease Control – Antivirals for Herpes Zoster: <a href="https://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Epid/CD%20Manual/Chapter%202%20-%20Imms/Shingles_Antivirals.pdf" target="_blank" rel="noopener">https://www.bccdc.ca/resource-gallery/Documents/Guidelines%20and%20Forms/Guidelines%20and%20Manuals/Epid/CD%20Manual/Chapter%202%20-%20Imms/Shingles_Antivirals.pdf</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
